Key result
Patient and lesion characteristics rarely drive DES selection, with ~87% of surveyed cardiologists using Xience.
Why the study?
Although DESs have continued to improve under regulatory approval for over 20 years, the criteria used by interventional cardiologists to select a DES remained to be investigated.
What are the criteria used by interventional cardiologists in Japan for selecting a drug-eluting stent?
Cross-Sectional (n=126)
What are the criteria used by interventional cardiologists in Japan for selecting a drug-eluting stent?
The selection of drug-eluting stents by interventional cardiologists in Japan is driven more by brand loyalty and company relationships than by patient or lesion characteristics, suggesting DES performance has reached physical limitations.
Answers are grounded in this paper and cite their sources.
Brand preferences may outweigh lesion factors in Japanese DES selection; leaves open effects on outcomes and generalizability.
More than 20 years have passed since the first company introduced drug-eluting stent (DES) in 2002, but competing companies still have improved their DESs under regulatory approval. This study aimed to investigate the criteria for interventional cardiologists performing percutaneous coronary intervention (PCI) in selecting a DES.From 10 April 2023, to 30 April 2023, 3,422 cardiologists were requested to complete a questionnaire, of whom 126 responded to the survey.Overall, 86.5% of the respondents used Xience cobalt-chromium everolimus-eluting stent (Xience) in > 10% of PCI procedures. For Xience, brand loyalty and calcified lesions were important independent variables for the DES selection criteria. Ultimaster sirolimus-eluting stent (Ultimaster) was not affected by the clinical data delivered by the company, whereas the respondents were shown to seek support for their activities from the Ultimaster supplier. The relationship with the company and/or sales representative and the planned surgical procedure affected the use of Coroflex ISAR NEO sirolimus-eluting polymer-free stent.Patient background and lesion characteristics had little impact on the DES selection criteria, suggesting that DES performance has already reached its physical limitations to the extent that respondents may not value further improvements in performance or characteristics of DES.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2023) conducted a cross-sectional in Percutaneous coronary intervention (PCI) (n=126). Drug-eluting stents (DES) was evaluated on Criteria for selecting a drug-eluting stent. A survey of 126 Japanese interventional cardiologists found that patient and lesion characteristics had little impact on drug-eluting stent selection, with 86.5% using Xience in >10% of procedures.
Synapse has enriched 10 related papers. Consider them for comparative context: